An in vitro study was performed that illustrates the benefit of CureMatch’s personalized combination therapy approach. The experiment used cancer cell lines that were derived from the tumors of patients. In the study, CureMatch used cell lines from human pancreatic adenocarcinoma tumors with eight mutations, two of which were deemed “actionable” – meaning that the CureMatch platform determined that […]
This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.
Otherwise, you will be redirected to the institutional part of this website.
Thank you for your understanding.